These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 30256257)
41. Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary. Vierkoetter KR; Ayabe AR; VanDrunen M; Ahn HJ; Shimizu DM; Terada KY Gynecol Oncol; 2014 Oct; 135(1):81-4. PubMed ID: 25093288 [TBL] [Abstract][Full Text] [Related]
42. Mismatch repair deficiency is rare in bone and soft tissue tumors. Lam SW; Kostine M; de Miranda NFCC; Schöffski P; Lee CJ; Morreau H; Bovée JVMG Histopathology; 2021 Oct; 79(4):509-520. PubMed ID: 33825202 [TBL] [Abstract][Full Text] [Related]
43. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy. Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579 [TBL] [Abstract][Full Text] [Related]
44. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264 [TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767 [TBL] [Abstract][Full Text] [Related]
46. Mismatch repair protein deficiency in endometriosis: Precursor of endometriosis-associated ovarian cancer in women with lynch syndrome. Yamaguchi M; Mikami Y; Kusunoki M; Yoshimura S; Motohara T; Kondoh E Taiwan J Obstet Gynecol; 2023 May; 62(3):448-452. PubMed ID: 37188452 [TBL] [Abstract][Full Text] [Related]
47. Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma. Vasan K; Satgunaseelan L; Anand S; Asher R; Selinger C; Low TH; Palme CE; Clark JR; Gupta R Pathology; 2019 Dec; 51(7):688-695. PubMed ID: 31630878 [TBL] [Abstract][Full Text] [Related]
48. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency. Clay MR; Allison KH; Folkins AK; Longacre TA Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635 [TBL] [Abstract][Full Text] [Related]
49. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression. Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958 [TBL] [Abstract][Full Text] [Related]
50. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study. Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707 [TBL] [Abstract][Full Text] [Related]
51. Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma. Gan Q; Crumley S; Broaddus RR Int J Gynecol Pathol; 2019 Jan; 38(1):44-51. PubMed ID: 29210800 [TBL] [Abstract][Full Text] [Related]